ArticleThe Journal of experimental medicine2002
Complement interaction with trypanosomatid promastigotes in normal human serum.
Article in The Journal of experimental medicine, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 66 citations in OpenAlex.
- Ex Vivo Analysis of the Association of GFP-ExpressingMicroorganisms · 2024Article
- Total serumiScience · 2023Article
- Morphogenesis Dynamics in Leishmania Differentiation.Pathogens (Basel, Switzerland) · 2022Article
- Stable Episomal TransfectantPathogens (Basel, Switzerland) · 2022Article
- Metalloprotease Gp63-Targeting Novel Glycoside Exhibits Potential Antileishmanial Activity.Frontiers in cellular and infection microbiology · 2022Article
- Antibody Targets and Properties for Complement-Fixation Against the Circumsporozoite Protein in Malaria Immunity.Frontiers in immunology · 2021Article
- Functional genomics in sand fly-derived Leishmania promastigotes.PLoS neglected tropical diseases · 2019Review
- Abnormal B-Cell Subset and Blimp-1-Mediated Humoral Responses Associated With Visceral Leishmaniasis Pathogenesis.The American journal of tropical medicine and hygiene · 2019Article
- Cutaneous Leishmaniasis: The Complexity of Host's Effective Immune Response against a Polymorphic Parasitic Disease.Journal of immunology research · 2019Review
- Human complement receptor type 1 (CR1) protein levels and genetic variants in chronic Chagas Disease.Scientific reports · 2018Article
- Geographical distribution of complement receptor type 1 variants and their associated disease risk.PloS one · 2017Article
- The Sand Fly Salivary Protein Lufaxin Inhibits the Early Steps of the Alternative Pathway of Complement by Direct Binding to the Proconvertase C3b-B.Frontiers in immunology · 2017Article
- Comment on "Regulation of immunity during visceral Leishmania infection" and further discussions about the role of antibodies in infections with Leishmania.Parasites & vectors · 2016Article
- Article
- Innate immunity against Leishmania infections.Cellular microbiology · 2015Review
- Deception and manipulation: the arms of leishmania, a successful parasite.Frontiers in immunology · 2014Review
- Article
- The emerging role of complement lectin pathway in trypanosomatids: molecular bases in activation, genetic deficiencies, susceptibility to infection, and complement system-based therapeutics.TheScientificWorldJournal · 2013Review
- Differential surface deposition of complement proteins on logarithmic and stationary phase Leishmania chagasi promastigotes.The Journal of parasitology · 2012Article
- Vaccine Development Against Leishmania donovani.Frontiers in immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In normal human serum (NHS), axenic promastigotes of Crithidia, Phytomonas, and Leishmania trigger complement activation, and from 1.2 to 1.8 x 10(5) C3 molecules are deposited per promastigote within 2.5 min. In Leishmania, promastigote C3 binding capacity remains constant during in vitro metacyclogenesis. C3 deposition on promastigotes activated through the classical complement pathway reaches a 50% maximum after similar50 s, and represents >85% of total C3 bound. In C1q- and C2-deficient human sera, promastigotes cannot activate the classical pathway (CP) unless purified C1q or C2 factors, respectively, are supplemented, demonstrating a requirement for CP factor in promastigote C3 opsonization. NHS depleted of natural anti-Leishmania antibodies cannot trigger promastigote CP activation, but IgM addition restores C3 binding. Furthermore, Leishmania binds natural antibodies in ethylenediaminetetracetic acid (EDTA)-treated NHS; after EDTA removal, promastigote-bound IgM triggers C3 deposition in natural antibody-depleted NHS. Serum collectins and pentraxins thus do not participate significantly in NHS promastigote C3 opsonization. Real-time kinetic analysis of promastigote CP-mediated lysis indicates that between 85--95% of parasites are killed within 2.5 min of serum contact. These data indicate that successful Leishmania infection in man must immediately follow promastigote transmission, and that Leishmania evasion strategies are shaped by the selective pressure exerted by complement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.